Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design.

Trail PA, Dubowchik GM, Lowinger TB.

Pharmacol Ther. 2018 Jan;181:126-142. doi: 10.1016/j.pharmthera.2017.07.013. Epub 2017 Jul 27. Review.

PMID:
28757155
2.

Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers.

Kelly MP, Hickey C, Makonnen S, Coetzee S, Jalal S, Wang Y, Delfino F, Shan J, Potocky TB, Chatterjee I, Andreev J, Kunz A, D'Souza C, Giurleo JT, Nittoli T, Trail PA, Thurston G, Kirshner JR.

Mol Cancer Ther. 2017 Jul;16(7):1299-1311. doi: 10.1158/1535-7163.MCT-16-0839. Epub 2017 Apr 4.

3.

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.

Papadopoulos KP, Kelley RK, Tolcher AW, Razak AR, Van Loon K, Patnaik A, Bedard PL, Alfaro AA, Beeram M, Adriaens L, Brownstein CM, Lowy I, Kostic A, Trail PA, Gao B, DiCioccio AT, Siu LL.

Clin Cancer Res. 2016 Mar 15;22(6):1348-55. doi: 10.1158/1078-0432.CCR-15-1221. Epub 2015 Oct 21.

4.

Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.

Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats S, Bosslet K, Chang YS.

Cancer Res. 2011 Feb 1;71(3):1029-40. doi: 10.1158/0008-5472.CAN-10-2274. Epub 2011 Jan 18.

5.

Antitumor activity of sorafenib in FLT3-driven leukemic cells.

Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, Zhang X, Wilkie D, Burd A, Shi H, Rocks S, Gedrich R, Abriola L, Vasavada H, Lynch M, Dumas J, Trail PA, Wilhelm SM.

Leukemia. 2007 Mar;21(3):439-45. Epub 2007 Jan 4.

PMID:
17205056
6.

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.

Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M, Wilhelm S.

Cancer Chemother Pharmacol. 2007 Apr;59(5):561-74. Epub 2006 Dec 8.

PMID:
17160391
8.

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA.

Cancer Res. 2004 Oct 1;64(19):7099-109.

9.

BR96 conjugates of highly potent anthracyclines.

King HD, Staab AJ, Pham-Kaplita K, Yurgaitis D, Firestone RA, Lasch SJ, Trail PA.

Bioorg Med Chem Lett. 2003 Jul 7;13(13):2119-22.

PMID:
12798317
10.

Monoclonal antibody drug immunoconjugates for targeted treatment of cancer.

Trail PA, King HD, Dubowchik GM.

Cancer Immunol Immunother. 2003 May;52(5):328-37. Epub 2003 Jan 16. Review.

PMID:
12700948
11.

Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains.

King HD, Dubowchik GM, Mastalerz H, Willner D, Hofstead SJ, Firestone RA, Lasch SJ, Trail PA.

J Med Chem. 2002 Sep 12;45(19):4336-43.

PMID:
12213074
12.

Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity.

Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K, Knipe JO, Lasch SJ, Trail PA.

Bioconjug Chem. 2002 Jul-Aug;13(4):855-69.

PMID:
12121142
13.

Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages.

Dubowchik GM, Radia S, Mastalerz H, Walker MA, Firestone RA, Dalton King H, Hofstead SJ, Willner D, Lasch SJ, Trail PA.

Bioorg Med Chem Lett. 2002 Jun 3;12(11):1529-32.

PMID:
12031335
14.

Synthesis of an immunoconjugate of camptothecin.

Walker MA, Dubowchik GM, Hofstead SJ, Trail PA, Firestone RA.

Bioorg Med Chem Lett. 2002 Jan 21;12(2):217-9.

PMID:
11755358
15.

Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291.

Naglich JG, Jure-Kunkel M, Gupta E, Fargnoli J, Henderson AJ, Lewin AC, Talbott R, Baxter A, Bird J, Savopoulos R, Wills R, Kramer RA, Trail PA.

Cancer Res. 2001 Dec 1;61(23):8480-5.

16.

Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin.

Wahl AF, Donaldson KL, Mixan BJ, Trail PA, Siegall CB.

Int J Cancer. 2001 Aug 15;93(4):590-600.

17.

Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells.

Salih HR, Kosowski SG, Haluska VF, Starling GC, Loo DT, Lee F, Aruffo AA, Trail PA, Kiener PA.

J Immunol. 2000 Sep 1;165(5):2903-10.

18.

Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.

Remsen LG, Trail PA, Hellström I, Hellström KE, Neuwelt EA.

Neurosurgery. 2000 Mar;46(3):704-9.

PMID:
10719867
19.

Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.

Trail PA, Willner D, Bianchi AB, Henderson AJ, TrailSmith MD, Girit E, Lasch S, Hellström I, Hellström KE.

Clin Cancer Res. 1999 Nov;5(11):3632-8.

20.

Monoclonal antibody drug conjugates in the treatment of cancer.

Trail PA, Bianchi AB.

Curr Opin Immunol. 1999 Oct;11(5):584-8. Review.

PMID:
10508711
21.

Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates.

King HD, Yurgaitis D, Willner D, Firestone RA, Yang MB, Lasch SJ, Hellström KE, Trail PA.

Bioconjug Chem. 1999 Mar-Apr;10(2):279-88.

PMID:
10077478
22.

Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis.

Ji WR, Castellino FJ, Chang Y, Deford ME, Gray H, Villarreal X, Kondri ME, Marti DN, Llinás M, Schaller J, Kramer RA, Trail PA.

FASEB J. 1998 Dec;12(15):1731-8.

PMID:
9837863
23.

Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis.

Ji WR, Barrientos LG, Llinás M, Gray H, Villarreal X, DeFord ME, Castellino FJ, Kramer RA, Trail PA.

Biochem Biophys Res Commun. 1998 Jun 18;247(2):414-9.

PMID:
9642142
24.
25.

Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.

Trail PA, Willner D, Knipe J, Henderson AJ, Lasch SJ, Zoeckler ME, TrailSmith MD, Doyle TW, King HD, Casazza AM, Braslawsky GR, Brown J, Hofstead SJ, Greenfield RS, Firestone RA, Mosure K, Kadow KF, Yang MB, Hellström KE, Hellström I.

Cancer Res. 1997 Jan 1;57(1):100-5.

26.

Immunoconjugates and immunotoxins for therapy of carcinomas.

Hellström I, Hellström KE, Siegall CB, Trail PA.

Adv Pharmacol. 1995;33:349-88. Review. No abstract available.

PMID:
7495675
27.

Drug immunotargeting for carcinomas: a reality at last?

Casazza AM, Trail PA, Hellström KE.

Ann Oncol. 1994 Oct;5(8):703-8. Review. No abstract available.

PMID:
7826902
28.

Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate.

Wang L, Yang CP, Horwitz SB, Trail PA, Casazza AM.

Cancer Chemother Pharmacol. 1994;34(2):96-102.

PMID:
8194172
29.

(6-Maleimidocaproyl)hydrazone of doxorubicin--a new derivative for the preparation of immunoconjugates of doxorubicin.

Willner D, Trail PA, Hofstead SJ, King HD, Lasch SJ, Braslawsky GR, Greenfield RS, Kaneko T, Firestone RA.

Bioconjug Chem. 1993 Nov-Dec;4(6):521-7.

PMID:
7508268
30.

Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.

Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellström I, Hellström KE.

Science. 1993 Jul 9;261(5118):212-5. Erratum in: Science 1994 Feb 25;263(5150):1076.

PMID:
8327892
31.

Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.

Friedman PN, Chace DF, Trail PA, Siegall CB.

J Immunol. 1993 Apr 1;150(7):3054-61.

PMID:
8454873
32.

BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells.

Friedman PN, McAndrew SJ, Gawlak SL, Chace D, Trail PA, Brown JP, Siegall CB.

Cancer Res. 1993 Jan 15;53(2):334-9.

33.

Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.

Trail PA, Willner D, Lasch SJ, Henderson AJ, Greenfield RS, King D, Zoeckler ME, Braslawsky GR.

Cancer Res. 1992 Oct 15;52(20):5693-700.

34.

Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30.

Rose WC, Basler GA, Trail PA, Saulnier M, Crosswell AR, Casazza AM.

Invest New Drugs. 1990;8 Suppl 1:S25-32.

PMID:
2380014
35.
36.
39.

Increase in the haemolytic complement activity of dogs affected with cyclic haematopoiesis.

Trail PA, Yang TJ, Cameron JA.

Vet Immunol Immunopathol. 1984 Oct;7(3-4):359-68.

PMID:
6506453

Supplemental Content

Loading ...
Support Center